PAV-615 (Neuroscience)

About Prosetta Biosciences

Prosetta Biosciences is a private, preclinical-stage biotech pioneering a novel drug discovery paradigm centered on modulating the assembly of cellular multi-protein complexes. Its platform, inspired by viral assembly mechanisms, has generated a pipeline with lead programs in neurodegenerative diseases like ALS/FTD and Alzheimer's, as well as in antiviral, antibacterial, and oncology indications. The company is led by founder and CEO/CTO Dr. Vishwanath R. Lingappa and is supported by a scientific advisory board including notable figures like Dr. Dale Bredesen. While demonstrating promising preclinical data, Prosetta remains pre-revenue and faces the significant risks inherent in advancing a first-in-class technology through clinical development.

Therapeutic Areas

Other C9orf72-associated ALS/FTD Drugs